TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MP-101 IN THE TREATMENT OF PSYCHOSIS IN PATIENTS WITH ALZHEIMER¿S DISEASE

Registry ID

MP-101-01

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

MEDITI PHARMA INC

Start date

2018-07-12

Completion date

2020-06-23

Last update

2017-02-17

Conditions

• PSYCHOTIC DISORDER
• ALZHEIMER'S DISEASE

Related clinical trials

• A PHASE 1/2A PLACEBO-CONTROLLED DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-MAPT-SC IN HEALTHY SUBJECTS AND SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.
• PHASE 2/3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXV-802 AND EXV- 801 IN THE TREATMENT OF AGITATION IN PARTICIPANTS WITH ALZHEIMER’S DISEASE DEMENTIA
• A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH A DOUBLE-BLIND PERIOD WITH OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN- 5288 IN ADULT PATIENTS WITH ALZHEIMER¿S DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF KARXT + KARX-EC FOR THE TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER’S DISEASE (ADAGIO-1)
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)

View on source registry